This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year:
Tarlatamab (Imdelltra), a bispecific antibody treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
Seniprutug (Tribuvia), a monoclonal antibody drug for ankylosing spondylitis, also known as axial spondyloarthritis or Bechterew-Strümpell syndrome.
This quarter saw notable progress in antibody drug discovery with machine learning, particularly with the advancements in generative AI, reducing development timelines and increasing the efficiency of targeting complex diseases. We delve into three companies to watch who are using AI for antibody drug discovery.
Q2 2024 witnessed major deals and acquisitions of up to $3 billion USD in value. Investment in antibodies is also continuing, with startup launches of up to $1 billion USD focused on AI, diseases such as obesity, and next-generation formats like antibody-peptide conjugates (APCs). We highlight three APCs currently in development, as well as weight-loss antibody medications.
There are several exciting antibodies to watch in Q3 which are either in regulatory review or in late-stage clinical trials. These antibodies range from those treating cancers to COVID-19 and skin diseases.
Register now for a free download of the report!
The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.
Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-
The FDA has revoked Emergency Use Authorizations (EUAs) for multiple COVID-19 monoclonal antibody (mAb) therapies, including those developed by Eli Lilly, AstraZeneca, Vir Biotechnology, and Regeneron. This decision reflects the challenges of targeting rapidly mutating viruses like SARS-CoV-2, which
ScientistとScience Exchangeとのご利用可能です。
